BMC Pharmacology

Table 1 Changes in hemodynamic parameters

From: Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure

	2.5 mg (n = 7)	7.5 mg (n = 12)	10 mg (n = 12)
PCWP [mmHg]	-7.3 ± 2.8 [-28 ± 10%]	-8.4 ± 3.1 [-36 ± 13%]	-9.3 ± 2.5 [-43 ± 11%]
MPAP [mmHg]	-8.9 ± 6.1 [-22 ± 12%]	-8.0 ± 3.3 [-24 ± 9%]	-7.3 ± 3.3 [-23 ± 8%]
RAP [mmHg]	-3.1 ± 3.5 [-26 ± 29%]	-4.3 ± 1.9 [-40 ± 15%]	-4.0 ± 2.3 [-39 ± 15%]
SVR [dyn•s•cm^-5]	-378 ± 550 [-15 ± 21%]	-523 ± 293 [-33 ± 15%]	-546 ± 267 [-31 ± 12%]
CI [L/min/m²]	+0.3 ± 0.3 [+17 ± 22%]	+0.6 ± 0.4 [+31 ± 22%]	+0.7 ± 0.5 [+33 ± 25%]

Changes from baseline (absolute and [relative] mean ± SD) of invasive hemodynamics after oral administration of 2.5, 7.5 and 10 mg BAY60-4552, p < 0.05 (for each change from baseline).

Back to article page